Anticoagulants or antiplatelets (APs) to prevent stroke in non-rheumatic atrial fibrillation and flutter*
| Outcomes† | Comparison | Weighted event rates | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| *Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data in article. | ||||
| †Duration of follow up not reported. | ||||
| ‡Random effects model was used. | ||||
| Stroke | Warfarin v placebo | 2.9% v 8.7% | 66% (52 to 76) | 18 (14 to 25) |
| Aspirin v placebo‡ | 9.1% v 11.2% | 16% (−28 to 45) | Not significant | |
| Warfarin v APs | 3.2% v 5.0% | 36% (10 to 54) | 56 (33 to 250) | |
| Warfarin v aspirin | 3.6% v 5.4% | 33% (3 to 54) | 56 (29 to 500) | |
| RRI (CI) | NNH (CI) | |||
| Haemorrhage | Warfarin v placebo | 2.2% v 0.9% | 139% (27 to 348) | 77 (46 to 250) |
| RRR (CI) | NNT | |||
| Aspirin v placebo | 1.3% v 1.4% | 5% (−81 to 51) | Not significant | |
| RRI (CI) | NNH | |||
| Warfarin v APs | 1.5% v 0.8% | 83% (−6 to 258) | Not significant | |
| Warfarin v aspirin | 1.6% v 1.0% | 56 (−24 to 221) | Not significant | |